SequelSEC

Protagenic Therapeutics, Inc.\new PTIX

Pharmaceutical Preparations · CIK 0001022899 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-03-31
Operating income
-$4.50M
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

Protagenic Therapeutics, Inc.\new (PTIX) reported revenue of $0 and net income of $1.37M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Protagenic Therapeutics, Inc.\new’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Protagenic Therapeutics, Inc.\new income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-12-312023-12-312022-12-312021-12-312020-12-312016-12-312015-12-312014-06-30
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$4.50M-$2.59M-$5.70M-$4.53M-$3.56M-$4.14M-$2.55M-$2.23M-$1.03M-$975.00K
Net income$1.37M-$3.59M-$5.53M-$5.00M-$3.56M-$4.52M-$2.55M-$2.28M-$1.02M-$1.08M
Research & development$901.90K$376.74K$3.84M$3.06M$1.59M$1.14M$699.80K$417.87K$456.27KUnavailable
Weighted-average diluted sharesshares 2.33Mshares 5.37Mshares 4.90Mshares 4.34Mshares 4.32MUnavailableUnavailableUnavailableUnavailableshares 400.00M
Pretax income$1.37M-$3.59M-$5.53M-$5.00M-$3.56M-$4.52M-$2.55M-$2.28M-$1.02M-$924.00K
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0Unavailable
Diluted EPS$0.59$-0.67$-1.13$-1.15$-0.82UnavailableUnavailableUnavailableUnavailable$0.00
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$332.39K$77.53K$1.76M$1.21M$1.97M$3.00M$1.85M$1.41M$568.76K$975.00K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Protagenic Therapeutics, Inc.\new balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-12-312023-12-312022-12-312021-12-312020-12-312016-12-312015-12-312014-06-30
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$671.09K$3.10M$3.34K$101.00K
Total assets$3.65M$89.09K$1.96M$4.32M$8.04M$11.06M$879.25K$3.16M$11.14K$246.00K
Current assets$1.54M$89.09K$1.88M$4.20M$8.04M$11.06M$879.25K$3.16M$3.34K$245.00K
Total liabilities$1.03M$5.04M$942.76K$655.25K$1.12M$1.12M$2.03MUnavailable$892.00K$316.00K
Current liabilities$1.03M$5.04M$942.76K$655.25K$1.12M$799.54K$655.19K$684.86K$678.36K$141.00K
Total equity incl. NCI$2.62M-$4.95M-$3.32M$3.67M$6.92M$9.94M-$1.15M$2.48M-$667.22K-$70.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailable$1.04KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$949.52K$961.12KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$138.00K

Cash flow

Protagenic Therapeutics, Inc.\new cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-12-312023-12-312022-12-312021-12-312020-12-312016-12-312015-12-312014-06-30
Operating cash flow-$2.81M-$1.77M-$4.22M-$3.70M-$1.99M-$2.80M-$1.35M-$1.14MUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.79K$1.00K
Investing cash flow$629.88KUnavailable$2.80M$4.78M$1.60M-$9.91MUnavailableUnavailableUnavailableUnavailable
Financing cash flow$3.87M$1.81M$1.96MUnavailableUnavailable$12.58M$1.22M$4.28MUnavailableUnavailable
Net change in cashUnavailableUnavailable$550.58K$1.07M-$325.98K-$129.92K-$127.53K$3.10M-$19.39K-$616.00K
Stock-based compensation$418.59KUnavailable$923.14K$666.83K$864.68K$1.52M$1.65M$546.13K$478.63K$275.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Protagenic Therapeutics, Inc.\new derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-12-312023-12-312022-12-312021-12-312020-12-312016-12-312015-12-312014-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.50x0.02x2.00x6.41x7.18x13.83x1.34x4.62x0.00x1.74x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PTIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-K · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-26View SEC filing
10-Q · Filed 2025-05-13View SEC filing
10-K · Filed 2025-03-31View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-12-31

Difference 4331276 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.